<p>Appendix A. Knowledge-based PrEP Questions </p><p>1. A recent study tested whether once daily PrEP could reduce the risk of HIV acquisition among at risk MSM and transgender women. This study demonstrated that PrEP reduced the risk of HIV acquisition OVERALL by:</p><p> 0-25%</p><p> 26-50%*</p><p> 51-75%</p><p> 76-100%</p><p>2. Similar studies of once daily PrEP in heterosexual discordant couples also showed reduction in HIV risk. These studies demonstrated that PrEP reduced the risk of HIV acquisition OVERALL by (Partners)</p><p> 0-25%</p><p> 26-50%</p><p> 51-75%*</p><p> 76-100%</p><p>3. For one group of people, there was more than one PrEP study completed, but the results were not consistent between the studies. Which group was that? (VoiceFem)</p><p> MSM</p><p> Elderly</p><p> Women*</p><p> Adolescents</p><p> Hispanics</p><p>4. Which medication has been FDA-approved for PrEP use? (FDA)</p><p> Maraviroc (Selzentry)</p><p> Tenofovir / Emtricitabine (Truvada)*</p><p> Tenofovir  Tenofovir / Emtricitabine / Efavirenz (Atripla)</p><p> Raltegravir + Emtracitabine (Isentress + Emtriva)</p><p> None has been approved</p><p> Not Sure</p><p>5. How often should patients on PrEP be followed for medication side effects and lab toxicities after initial assessment? (PrEPMonitor)</p><p> Every month</p><p> Every 3 months*</p><p> Every 6 months</p><p> Yearly</p><p> Not necessary to monitor after the first year</p>